STOCK TITAN

MultiPlan Reports Third Quarter 2024 Results and Updates 2024 Guidance

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

MultiPlan (NYSE: MPLN) reported Q3 2024 financial results with revenues of $230.5 million, down 5.1% year-over-year, and a net loss of $391.5 million, primarily due to a $361.6 million impairment charge for goodwill and indefinite-lived intangibles. Adjusted EBITDA was $141.6 million. The company processed $44.7 billion in claim charges, identifying potential medical cost savings of $6.4 billion, up 10% from Q3 2023. MultiPlan updated its FY 2024 guidance, tightening revenue expectations to $930-940 million and adjusting Adjusted EBITDA guidance to $580-590 million.

MultiPlan (NYSE: MPLN) ha riportato i risultati finanziari del terzo trimestre 2024 con ricavi di $230,5 milioni, in calo del 5,1% rispetto allo stesso periodo dell’anno precedente, e una perdita netta di $391,5 milioni, principalmente a causa di un addebito di svalutazione di $361,6 milioni per avviamento e intangibili a vita indefinita. L'EBITDA adeguato è stato di $141,6 milioni. L'azienda ha elaborato $44,7 miliardi in richieste di rimborso, identificando potenziali risparmi sui costi medici di $6,4 miliardi, in aumento del 10% rispetto al terzo trimestre del 2023. MultiPlan ha aggiornato le previsioni per l'anno fiscale 2024, restringendo le aspettative di ricavi a $930-940 milioni e adattando le previsioni di EBITDA adeguato a $580-590 milioni.

MultiPlan (NYSE: MPLN) reportó los resultados financieros del tercer trimestre de 2024 con ingresos de $230.5 millones, una disminución del 5.1% en comparación con el año anterior, y una pérdida neta de $391.5 millones, principalmente debido a un cargo por deterioro de $361.6 millones por buena voluntad e intangibles de vida indefinida. El EBITDA ajustado fue de $141.6 millones. La compañía procesó $44.7 mil millones en cargos de reclamaciones, identificando posibles ahorros en costos médicos de $6.4 mil millones, un incremento del 10% en comparación con el tercer trimestre de 2023. MultiPlan actualizó sus previsiones para el año fiscal 2024, ajustando las expectativas de ingresos a $930-940 millones y ajustando las proyecciones de EBITDA ajustado a $580-590 millones.

멀티플랜 (NYSE: MPLN)은 2024년 3분기 재무 결과를 보고했으며, 수익은 $230.5백만으로 작년 대비 5.1% 감소하였고, 순손실은 $391.5백만에 달했으며, 주로 $361.6백만의 영업권 및 무기한 자산에 대한 손상차손 때문입니다. 조정 EBITDA는 $141.6백만이었습니다. 회사는 $44.7억의 청구 비용을 처리하며, 2023년 3분기 대비 10% 증가한 $6.4억의 잠재적인 의료 비용 절감을 확인했습니다. 멀티플랜은 2024 회계연도의 가이던스를 업데이트하며, 수익 예상치를 $930-940백만으로 좁히고 조정 EBITDA 가이던스를 $580-590백만으로 조정했습니다.

MultiPlan (NYSE: MPLN) a annoncé ses résultats financiers pour le troisième trimestre 2024, avec des revenus de $230,5 millions, en baisse de 5,1 % par rapport à l'année précédente, et une perte nette de $391,5 millions, principalement en raison d'une charge de dépréciation de $361,6 millions pour goodwill et actifs incorporels à durée de vie indéfinie. L'EBITDA ajusté s'élevait à $141,6 millions. L'entreprise a traité $44,7 milliards en demandes de remboursement, identifiant des économies potentielles sur les coûts médicaux s'élevant à $6,4 milliards, soit une augmentation de 10 % par rapport au troisième trimestre de 2023. MultiPlan a mis à jour ses prévisions pour l'exercice 2024, en resserrant les attentes de revenus à $930-940 millions et en ajustant les prévisions d'EBITDA ajusté à $580-590 millions.

MultiPlan (NYSE: MPLN) berichtete über die finanziellen Ergebnisse für das 3. Quartal 2024 mit Einnahmen von $230,5 Millionen, einem Rückgang von 5,1 % im Vergleich zum Vorjahr, und einem Nettoverlust von $391,5 Millionen, hauptsächlich aufgrund eines Abwertungsaufwands von $361,6 Millionen für Geschäfts- und immaterielle Werte mit unbegrenzter Lebensdauer. Das bereinigte EBITDA betrug $141,6 Millionen. Das Unternehmen bearbeitete $44,7 Milliarden an Ansprüchen und identifizierte mögliche Einsparungen bei den Gesundheitskosten in Höhe von $6,4 Milliarden, was einem Anstieg von 10 % im Vergleich zum 3. Quartal 2023 entspricht. MultiPlan aktualisierte seine Prognose für das Geschäftsjahr 2024 und passte die Umsatzprognose auf $930-940 Millionen sowie die bereinigte EBITDA-Prognose auf $580-590 Millionen an.

Positive
  • Potential medical cost savings increased 10% YoY to $6.4 billion
  • Maintained stable operating cash flow at $72.8 million
  • $86.6 million in unrestricted cash and cash equivalents
Negative
  • Revenue declined 5.1% YoY to $230.5 million
  • $391.5 million net loss, including $361.6 million impairment charge
  • Adjusted EBITDA decreased from $152.3M to $141.6M YoY
  • Lowered top end of FY 2024 revenue and Adjusted EBITDA guidance

Insights

The Q3 results reveal significant challenges for MultiPlan, with concerning financial metrics. Revenue declined by 5.1% to $230.5 million, while the company reported a substantial net loss of $391.5 million, primarily due to a $361.6 million goodwill impairment charge. The impairment suggests management's acknowledgment of diminished future growth prospects.

The revised 2024 guidance indicates continued pressure, with revenue expectations tightened downward to $930-940 million from the previous $935-955 million range. While the company maintains strong cash flow generation with $72.8 million from operations, the high interest expense guidance of $320-330 million remains a significant burden on profitability.

The transformation strategy toward becoming a data and technology company appears necessary but carries execution risks during a period of financial strain. The debt load and interest expenses continue to constrain financial flexibility.

The 10% year-over-year increase in identified potential medical cost savings to $6.4 billion demonstrates MultiPlan's core value proposition remains intact. However, the declining revenue despite higher savings identification suggests pricing pressure and challenges in monetizing these opportunities.

The appointment of a new Chief Growth Officer signals a strategic pivot toward sales expansion, but the goodwill impairment indicates the market values MultiPlan's future growth prospects less optimistically than before. The healthcare cost management space faces increasing competition and pressure to demonstrate value, making the company's transformation important but challenging.

Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million

Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024

NEW YORK--(BUSINESS WIRE)-- MultiPlan Corporation (“MultiPlan” or the “Company”) (NYSE: MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance.

CEO Travis Dalton said, “During the third quarter, we experienced growth in volumes of billed charges and identified potential savings. Our Revenues and Adjusted EBITDA were in line with the low end of our guidance for the third quarter. We are tightening our Revenues guidance with a modest decrease to the top end of our Adjusted EBITDA guidance for full year 2024. We anticipate the fourth quarter to run similar to our third quarter.”

“As I shared with our second quarter earnings results, I remain confident in this Company and its transformation journey. With the building of my leadership team nearly complete, this talented team has already marched forward to clearly establish the framework for developing a data and insights driven and technology focused company that is fit for growth,” said Mr. Dalton.

“With our new CFO just having completed his first 90 days at MultiPlan, we are thrilled to also welcome Tiffani Misencik into our newly created Chief Growth Officer role that is focused on our sales organization. I am extremely proud of the leadership team and talent we have been able to attract and the progress we are making. Our leaders are embedding a growth focused culture where everyone listens, problem solves and is here to serve our clients.”

Mr. Dalton concluded, “Our multi-year transformation towards a world-class data and technology company is underway. We will work with all stakeholders of the healthcare continuum to positively impact increased transparency, improved quality and lower costs. This focus will provide the platform for our long-term sustainable growth. I look forward to sharing the big mileposts of our transformation journey in the months and quarters to come.”

Business and Financial Highlights

  • Revenues of $230.5 million for Q3 2024, a decrease of 5.1%, compared to revenues of $242.8 million for Q3 2023.
  • Net loss of $391.5 million for Q3 2024, compared to net loss of $24.1 million for Q3 2023. The net loss was principally due to an impairment charge of $361.6 million for goodwill and indefinite-lived intangibles.
  • Adjusted EBITDA of $141.6 million for Q3 2024, compared to Adjusted EBITDA of $152.3 million for Q3 2023.
  • Net cash provided by operating activities of $72.8 million for Q3 2024, compared to net cash provided by operating activities of $72.1 million for Q3 2023.
  • Free Cash Flow of $41.1 million for Q3 2024, compared to Free Cash Flow of $49.7 million for Q3 2023.
  • The Company ended Q3 2024 with $86.6 million of unrestricted cash and cash equivalents on the balance sheet.
  • The Company processed approximately $44.7 billion in claim charges during Q3 2024, identifying potential medical cost savings of approximately $6.4 billion.
  • Based on the results of an impairment test as of September 30, 2024, the estimated fair values of our goodwill and indefinite-lived assets were less than their carrying value and as a result impairment charges of $355.8 million for our goodwill and $5.8 million for our indefinite-lived intangibles were recorded.

2024 Financial Guidance

The Company is updating certain metrics for its full-year 2024 guidance, as detailed in the table below:

Financial Metric

 

Prior FY 2024 Guidance

 

Updated FY 2024 Guidance

Revenues

 

$935 million to $955 million

 

$930 million to $940 million

Adjusted EBITDA1

 

$580 million to $595 million

 

$580 million to $590 million

Interest expense

 

$320 million to $330 million

 

(unchanged)

Cash flow from operations

 

$135 million to $150 million

 

$135 million to $145 million

Capital expenditures

 

$120 million to $130 million

 

(unchanged)

Depreciation

 

$80 million to $90 million

 

(unchanged)

Amortization of intangible assets

 

$345 million to $350 million

 

(unchanged)

Effective tax rate

 

25% to 28%

 

(unchanged)

Conference Call Information

The Company will host a conference call today, Tuesday, November 5, 2024 at 8:30 a.m. U.S. Eastern Time (ET) to discuss its financial results. To join the conference call, please pre-register using the following link at least ten minutes before the call begins: https://www.netroadshow.com/events/login?show=95da760a&confId=71678. Upon registration, you will receive an email with the conference dial-in details and a unique access code and pin.

A live webcast of the conference call can be accessed through the Investor Relations section of the Company’s website at investors.multiplan.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. This earnings press release and a supplemental slide deck will also be available on this section of the Company’s website.

1 We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP (as defined below) measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

For those unable to listen to the live conference call, a replay will be available approximately two hours after the call through the archived webcast on the Investor Relations section of the Company’s website.

About MultiPlan

MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the U.S. healthcare system. Our focus is on identifying medical savings, helping to lower out-of-pocket costs, and reducing or eliminating balance billing for healthcare consumers. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.

Forward Looking Statements

This press release includes statements that express our management’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “forecasts,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release, including the discussion of 2024 outlook and guidance, additions to our leadership team, and the Company’s ongoing transformation, and the long-term prospects of the Company. Such forward-looking statements are based on available current market information and management’s expectations, beliefs and forecasts concerning future events impacting the business. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that these forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These factors include: loss of our customers, particularly our largest customers; interruptions or security breaches of our information technology systems and other cybersecurity attacks; the impact of reduced claims volumes resulting from a nationwide outage by a vendor used by our customers; the ability to achieve the goals of our strategic plans and recognize the anticipated strategic, operational, growth and efficiency benefits when expected; our ability to enter new lines of business and broaden the scope of our services; the loss of key members of management team or inability to maintain sufficient qualified personnel; our ability to continue to attract, motivate and retain a large number of skilled employees, and adapt to the effects of inflationary pressure on wages; trends in the U.S. healthcare system, including recent trends of unknown duration of reduced healthcare utilization and increased patient financial responsibility for services; effects of competition; effects of pricing pressure; our ability to identify, complete and successfully integrate acquisitions; the inability of our customers to pay for our services; changes in our industry and industry standards and technology; our ability to protect proprietary information, processes and applications; our ability to maintain the licenses or right of use for the software we use; our inability to expand our network infrastructure; our ability to obtain additional financing; our ability to pay interest and principal on our notes and other indebtedness; lowering or withdrawal of our credit ratings; adverse outcomes related to litigation or governmental proceedings; inability to preserve or increase our market share or the size of our PPO networks; decreases in discounts from providers; pressure to limit access to preferred provider networks; the loss of our existing relationships with providers; changes in our regulatory environment, including healthcare law and regulations; the expansion of privacy and security laws; heightened enforcement activity by government agencies; the possibility that we may be adversely affected by other political economic, business and/or competitive factors; changes in accounting principles or the incurrence of impairment charges our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting; other factors disclosed in our Securities and Exchange Commission (“SEC”) filings from time to time, including, without limitation, those factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our filings with the SEC; and other factors beyond our control. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

There can be no assurance that future developments affecting our business will be those that we have anticipated. Forward-looking statements speak only as of the date made.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), this press release contains certain non-GAAP financial measures, including EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and Adjusted Cash Conversion Ratio. A non-GAAP financial measure is generally defined as a numerical measure of a company’s financial or operating performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP.

EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and Adjusted Cash Conversion Ratio are supplemental measures of MultiPlan’s performance that are not required by or presented in accordance with GAAP. These measures are not measurements of our financial or operating performance under GAAP, have limitations as analytical tools and should not be considered in isolation or as an alternative to net income, cash flows or any other measures of performance prepared in accordance with GAAP.

EBITDA represents net income before interest expense, interest income, income tax provision, depreciation, amortization of intangible assets, and non-income taxes. Adjusted EBITDA is EBITDA as further adjusted by certain items as described in the table below.

In addition, in evaluating EBITDA and Adjusted EBITDA you should be aware that, in the future, we may incur expenses similar to the adjustments in the presentation of EBITDA and Adjusted EBITDA. The presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. The calculations of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Based on our industry and debt financing experience, we believe that EBITDA and Adjusted EBITDA are customarily used by investors, analysts and other interested parties to provide useful information regarding a company’s ability to service and/or incur indebtedness.

We also believe that Adjusted EBITDA is useful to investors and analysts in assessing our operating performance during the periods these charges were incurred on a consistent basis with the periods during which these charges were not incurred. Both EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider either in isolation, or as a substitute for analysis of our results as reported under GAAP. Some of the limitations are:

  • EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs;
  • EBITDA and Adjusted EBITDA do not reflect interest expense, or the cash requirements necessary to service interest or principal payments on our debt;
  • EBITDA and Adjusted EBITDA do not reflect our tax expense or the cash requirements to pay our taxes; and
  • Although depreciation and amortization are non-cash charges, the tangible assets being depreciated will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements.

MultiPlan’s presentation of Adjusted EBITDA should not be construed as an inference that our future results and financial position will be unaffected by unusual items.

Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, all as disclosed in the Statements of Cash Flows. Unlevered Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, plus cash interest paid, all as disclosed in the Statements of Cash Flows. Free Cash Flow and Unlevered Free Cash Flow are measures of our operational performance used by management to evaluate our business after purchases of property and equipment and, in the case of Unlevered Free Cash Flow, prior to the impact of our capital structure. Free Cash Flow and Unlevered Free Cash Flow should be considered in addition to, rather than as a substitute for, consolidated net income as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, MultiPlan’s definitions of Free Cash Flow and Unlevered Free Cash Flow are limited, in that they do not represent residual cash flows available for discretionary expenditures, due to the fact that the measures do not deduct the payments required for debt service, in the case of Unlevered Free Cash Flow, and other contractual obligations or payments made for business acquisitions.

Adjusted Cash Conversion Ratio is defined as Unlevered Free Cash Flow divided by Adjusted EBITDA. MultiPlan believes that the presentation of the Adjusted Cash Conversion Ratio provides useful information to investors because it is a financial performance measure that shows how much of its Adjusted EBITDA MultiPlan converts into Unlevered Free Cash Flow.

MULTIPLAN CORPORATION

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

 

September 30,
2024

 

December 31,
2023

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

86,598

 

 

$

71,547

 

Restricted cash

 

10,570

 

 

 

9,947

 

Trade accounts receivable, net

 

82,132

 

 

 

76,558

 

Prepaid expenses

 

16,536

 

 

 

23,432

 

Prepaid taxes

 

 

 

 

1,364

 

Unbilled IDR fees, net

 

13,975

 

 

 

8,197

 

Other current assets, net

 

1,719

 

 

 

2,548

 

Total current assets

 

211,530

 

 

 

193,593

 

Property and equipment, net

 

292,870

 

 

 

267,429

 

Operating lease right-of-use assets

 

13,572

 

 

 

19,680

 

Goodwill

 

2,403,140

 

 

 

3,829,002

 

Other intangibles, net

 

2,366,794

 

 

 

2,633,207

 

Other assets, net

 

31,298

 

 

 

21,776

 

Total assets

$

5,319,204

 

 

$

6,964,687

 

Liabilities and Shareholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

22,547

 

 

$

19,590

 

Accrued interest

 

74,314

 

 

 

56,827

 

Accrued taxes

 

8,123

 

 

 

 

Operating lease obligation, short-term

 

4,585

 

 

 

4,792

 

Current portion of long-term debt

 

13,250

 

 

 

13,250

 

Accrued compensation

 

33,624

 

 

 

44,720

 

Accrued legal contingencies

 

23,123

 

 

 

12,123

 

Other accrued expenses

 

21,931

 

 

 

15,437

 

Total current liabilities

 

201,497

 

 

 

166,739

 

Long-term debt

 

4,510,245

 

 

 

4,532,733

 

Operating lease obligation, long-term

 

9,716

 

 

 

17,124

 

Private Placement Warrants and Unvested Founder Shares

 

1

 

 

 

477

 

Deferred income taxes

 

378,508

 

 

 

521,707

 

Other liabilities

 

11,675

 

 

 

16,783

 

Total liabilities

 

5,111,642

 

 

 

5,255,563

 

Shareholders’ equity:

 

 

 

Shareholder interests

 

 

 

Preferred stock, $0.0001 par value — 10,000,000 shares authorized; no shares issued

 

 

 

 

 

Common stock, $0.0001 par value — 1,500,000,000 shares authorized; 16,914,056 and 16,695,207 issued; 16,171,197 and 16,207,984 shares outstanding(1)

 

2

 

 

 

2

 

Additional paid-in capital(1)

 

2,365,928

 

 

 

2,348,570

 

Accumulated other comprehensive loss

 

(12,462

)

 

 

(11,778

)

Retained deficit

 

(2,007,173

)

 

 

(499,307

)

Treasury stock — 742,859 and 487,223 shares(1)

 

(138,733

)

 

 

(128,363

)

Total shareholders’ equity

 

207,562

 

 

 

1,709,124

 

Total liabilities and shareholders’ equity

$

5,319,204

 

 

$

6,964,687

 

(1)Shares, common stock and additional paid-in capital have been retroactively adjusted for all periods presented to reflect the one-for-forty (1-for-40) reverse stock split that became effective on September 20, 2024.

MULTIPLAN CORPORATION

Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss

(in thousands, except share and per share data)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenues

$

230,495

 

 

$

242,804

 

 

$

698,479

 

 

$

717,389

 

Costs of services (exclusive of depreciation and amortization of intangible assets shown below)

 

60,825

 

 

 

60,949

 

 

 

182,271

 

 

 

174,806

 

General and administrative expenses

 

37,725

 

 

 

36,779

 

 

 

107,133

 

 

 

107,996

 

Depreciation

 

22,572

 

 

 

19,586

 

 

 

65,372

 

 

 

56,693

 

Amortization of intangible assets

 

85,971

 

 

 

85,971

 

 

 

257,913

 

 

 

256,724

 

Loss on impairment of goodwill and intangible assets

 

361,612

 

 

 

 

 

 

1,434,363

 

 

 

 

Total expenses

 

568,705

 

 

 

203,285

 

 

 

2,047,052

 

 

 

596,219

 

Operating (loss) income

 

(338,210

)

 

 

39,519

 

 

 

(1,348,573

)

 

 

121,170

 

Interest expense

 

81,792

 

 

 

84,300

 

 

 

245,119

 

 

 

250,203

 

Interest income

 

(1,245

)

 

 

(1,505

)

 

 

(2,722

)

 

 

(7,110

)

Gain on extinguishment of debt

 

 

 

 

(10,129

)

 

 

(5,913

)

 

 

(46,907

)

(Gain) loss on change in fair value of Private Placement Warrants and Unvested Founder Shares

 

(87

)

 

 

(2,127

)

 

 

(476

)

 

 

267

 

Net loss before taxes

 

(418,670

)

 

 

(31,020

)

 

 

(1,584,581

)

 

 

(75,283

)

Benefit for income taxes

 

(27,220

)

 

 

(6,875

)

 

 

(76,715

)

 

 

(14,977

)

Net loss

$

(391,450

)

 

$

(24,145

)

 

$

(1,507,866

)

 

$

(60,306

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding – Basic(1)

 

16,143,520

 

 

 

16,161,095

 

 

 

16,139,523

 

 

 

16,096,395

 

Weighted average shares outstanding – Diluted(1)

 

16,143,520

 

 

 

16,161,095

 

 

 

16,139,523

 

 

 

16,096,395

 

 

 

 

 

 

 

 

 

Net loss per share – Basic(1)

$

(24.25

)

 

$

(1.49

)

 

$

(93.43

)

 

$

(3.75

)

Net loss per share – Diluted(1)

$

(24.25

)

 

$

(1.49

)

 

$

(93.43

)

 

$

(3.75

)

 

 

 

 

 

 

 

 

Net loss

 

(391,450

)

 

 

(24,145

)

 

 

(1,507,866

)

 

 

(60,306

)

Other comprehensive income:

 

 

 

 

 

 

 

Change in unrealized gains (losses) on interest rate swaps, net of tax

 

(11,341

)

 

 

382

 

 

 

(684

)

 

 

382

 

Comprehensive loss

$

(402,791

)

 

$

(23,763

)

 

$

(1,508,550

)

 

$

(59,924

)

(1)Shares and net loss per share have been retroactively adjusted for all periods presented to reflect the one-for-forty (1-for-40) reverse stock split that became effective on September 20, 2024.

MULTIPLAN CORPORATION

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

Operating activities:

 

 

 

Net loss

$

(1,507,866

)

 

$

(60,306

)

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation

 

65,372

 

 

 

56,693

 

Amortization of intangible assets

 

257,913

 

 

 

256,724

 

Amortization of the right-of-use asset

 

3,377

 

 

 

4,329

 

Loss on impairment of goodwill and intangible assets

 

1,434,363

 

 

 

 

Stock-based compensation

 

19,829

 

 

 

13,357

 

Deferred income taxes

 

(142,999

)

 

 

(87,278

)

Amortization of debt issuance costs and discounts

 

8,788

 

 

 

7,967

 

Gain on extinguishment of debt

 

(5,913

)

 

 

(46,907

)

Loss on disposal of property and equipment

 

155

 

 

 

452

 

(Gain) loss on change in fair value of Private Placement Warrants and Unvested Founder Shares

 

(476

)

 

 

267

 

Changes in assets and liabilities:

 

 

 

Accounts receivable, net

 

(5,574

)

 

 

11,621

 

Prepaid expenses and other assets

 

(9,466

)

 

 

(759

)

Prepaid taxes

 

1,364

 

 

 

(5,224

)

Operating lease obligation

 

(4,884

)

 

 

(5,041

)

Accounts payable, accrued interest, accrued taxes, accrued expenses, legal contingencies and other

 

27,046

 

 

 

(1,877

)

Net cash provided by operating activities

 

141,029

 

 

 

144,018

 

Investing activities:

 

 

 

Purchases of property and equipment

 

(87,689

)

 

 

(77,509

)

BST Acquisition, net of cash acquired

 

 

 

 

(140,940

)

Net cash used in investing activities

 

(87,689

)

 

 

(218,449

)

Financing activities:

 

 

 

Repurchase of 5.750% Notes

 

 

 

 

(134,975

)

Repayments of Term Loan B

 

(9,938

)

 

 

(9,938

)

Repurchase of Senior Convertible PIK Notes

 

(14,886

)

 

 

 

Taxes paid on settlement of vested share awards

 

(3,355

)

 

 

(461

)

Purchase of treasury stock

 

(10,370

)

 

 

(13,140

)

Proceeds from issuance of common stock under Employee Stock Purchase Plan

 

883

 

 

 

 

Net cash used in financing activities

 

(37,666

)

 

 

(158,514

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

15,674

 

 

 

(232,945

)

Cash, cash equivalents and restricted cash at beginning of period

 

81,494

 

 

 

340,559

 

Cash, cash equivalents and restricted cash at end of period

$

97,168

 

 

$

107,614

 

 

 

 

 

Cash and cash equivalents

$

86,598

 

 

$

101,320

 

Restricted cash

 

10,570

 

 

 

6,294

 

Cash, cash equivalents and restricted cash at end of period

$

97,168

 

 

$

107,614

 

 

 

 

 

Noncash investing and financing activities:

 

 

 

Purchases of property and equipment not yet paid

$

11,928

 

 

$

7,319

 

Supplemental disclosure of cash flow information:

 

 

 

Cash paid during the period for:

 

 

 

Interest

$

(218,590

)

 

$

(223,640

)

Income taxes, net of refunds

$

(57,860

)

 

$

(78,582

)

MULTIPLAN CORPORATION

Calculation of EBITDA and Adjusted EBITDA

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

(in thousands)

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Net loss

$

(391,450

)

 

$

(24,145

)

 

$

(1,507,866

)

 

$

(60,306

)

Adjustments:

 

 

 

 

 

 

 

Interest expense

 

81,792

 

 

 

84,300

 

 

 

245,119

 

 

 

250,203

 

Interest income

 

(1,245

)

 

 

(1,505

)

 

 

(2,722

)

 

 

(7,110

)

Benefit for income taxes

 

(27,220

)

 

 

(6,875

)

 

 

(76,715

)

 

 

(14,977

)

Depreciation

 

22,572

 

 

 

19,586

 

 

 

65,372

 

 

 

56,693

 

Amortization of intangible assets

 

85,971

 

 

 

85,971

 

 

 

257,913

 

 

 

256,724

 

Non-income taxes

 

515

 

 

 

669

 

 

 

1,623

 

 

 

1,672

 

EBITDA

$

(229,065

)

 

$

158,001

 

 

$

(1,017,276

)

 

$

482,899

 

Adjustments:

 

 

 

 

 

 

 

Other expenses (income), net(1)

 

1,517

 

 

 

521

 

 

 

2,584

 

 

 

759

 

Integration expenses

 

850

 

 

 

891

 

 

 

1,994

 

 

 

2,722

 

Change in fair value of Private Placement Warrants and unvested founder shares

 

(87

)

 

 

(2,127

)

 

 

(476

)

 

 

267

 

Transaction-related expenses

 

 

 

 

269

 

 

 

 

 

 

8,105

 

Gain on extinguishment of debt

 

 

 

 

(10,129

)

 

 

(5,913

)

 

 

(46,907

)

Loss on impairment of goodwill and intangible assets

 

361,612

 

 

 

 

 

 

1,434,363

 

 

 

 

Stock-based compensation

 

6,818

 

 

 

4,835

 

 

 

19,829

 

 

 

13,357

 

Adjusted EBITDA

$

141,645

 

 

$

152,261

 

 

$

435,105

 

 

$

461,202

 

(1) "Other expenses (income), net" represent miscellaneous non-recurring income, miscellaneous non-recurring expense, gain or loss on disposal of assets, impairment of other assets, gain or loss on disposal of leases, tax penalties, and non-integration related severance costs.

Calculation of Unlevered Free Cash Flow and Adjusted Cash Conversion Ratio

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

(in thousands)

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Net cash provided by operating activities

$

72,842

 

 

$

72,118

 

 

$

141,029

 

 

$

144,018

 

Purchases of property and equipment

 

(31,700

)

 

 

(22,414

)

 

 

(87,689

)

 

 

(77,509

)

Free Cash Flow

 

41,142

 

 

 

49,704

 

 

 

53,340

 

 

 

66,509

 

Interest paid

 

60,195

 

 

 

62,156

 

 

 

218,590

 

 

 

223,640

 

Unlevered Free Cash Flow

$

101,337

 

 

$

111,860

 

 

$

271,930

 

 

$

290,149

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

141,645

 

 

$

152,261

 

 

$

435,105

 

 

$

461,202

 

Adjusted Cash Conversion Ratio

 

72

%

 

 

73

%

 

 

62

%

 

 

63

%

 

 

 

 

 

 

 

 

Net cash used in investing activities

$

(31,700

)

 

 

(22,060

)

 

$

(87,689

)

 

$

(218,449

)

Net cash used in financing activities

$

(3,143

)

 

 

(38,338

)

 

$

(37,666

)

 

$

(158,514

)

 

Investor Relations



Jason Wong

SVP, Treasury & Investor Relations

and

Shawna Gasik

AVP, Investor Relations

866-909-7427

investor@multiplan.com

Source: MultiPlan Corporation

FAQ

What was MultiPlan's (MPLN) revenue in Q3 2024?

MultiPlan reported revenues of $230.5 million in Q3 2024, representing a 5.1% decrease from $242.8 million in Q3 2023.

Why did MultiPlan (MPLN) report a large net loss in Q3 2024?

MultiPlan reported a net loss of $391.5 million in Q3 2024 primarily due to a $361.6 million impairment charge for goodwill and indefinite-lived intangibles.

What is MultiPlan's (MPLN) updated revenue guidance for 2024?

MultiPlan updated its FY 2024 revenue guidance to $930-940 million, down from the previous guidance of $935-955 million.

MultiPlan Corporation

NYSE:MPLN

MPLN Rankings

MPLN Latest News

MPLN Stock Data

136.57M
16.14M
302.78%
3328.1%
2.28%
Health Information Services
Services-business Services, Nec
Link
United States of America
NEW YORK